

**ARUP Physician Services 004070
321 TESTING ANSR EXTRACT
Salt Lake City NY 84108**

Date of Birth:
Gender: Unknown
ARUP ID: 523104
Requisition #:
Client Supplied ID:
Physician: TEST, DR
Printed: 13-Sep-18 10:07:49



<u>Procedure</u>	<u>Result</u>	<u>Units</u>	<u>Ref Interval</u>	<u>Accession</u>	<u>Collected</u>	<u>Received</u>	<u>Reported/</u> <u>Verified</u>
Number of Markers	13	markers		18-256-900033	13-Sep-18 09:42:00	13-Sep-18 10:03:00	13-Sep-18 10:06:09
B-ALL MRD (COG Protocol) Interpretation	See Note f			18-256-900033	13-Sep-18 09:42:00	13-Sep-18 10:03:00	13-Sep-18 10:06:09
Technical B-ALL MRD, 13 markers	Billed			18-256-900033	13-Sep-18 09:42:00	13-Sep-18 10:03:00	13-Sep-18 10:06:15

13-Sep-18 09:42:00 B-ALL MRD (COG Protocol) Interpretation:
SAMPLE: BONE MARROW (COG DAY 29) IMPRESSION:
An abnormal immature B-cell population is not identified See comment.

COMMENT:
There are no abnormal immature B-cells detected, thus no evidence of residual B lymphoblastic leukemia/lymphoma.

Markers run: CD3, CD9, CD10, CD13, CD19, CD20, CD33, CD34, CD38, CD45, CD58, CD71, Syto16.

These results have been reviewed and approved by Rodney Miles, MD, PhD.

13-Sep-18 09:42:00 B-ALL MRD (COG Protocol) Interpretation:
INTERPRETIVE INFORMATION: B-ALL MRD By Flow Cytometry
(COG Protocol)

For Day 29 samples: Limit of detection of B-ALL blasts is 0.01 percent of mononuclear cells.
For Day 8 samples: Limit of detection of B-ALL blasts is 0.01 percent of total nucleated cells.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement A: aruplab.com/CS

* = Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab